Brittney C. Whiting, Vickie and Willie Edwards, parents of Brittney Whiting v Junique Morris
P/A Dino S. Columbo; Judge NA
* In April 2009, Junique Morris was driving her Toyota Rav 4 SUV and struck Brittney Whiting while she was in the crosswalk at the intersection of High and Fayette Streets in downtown Morgantown. After hitting Whiting with her vehicle, Morris fled the scene of the accident. Whiting suffered severe and permanent injuries including multiple fractures to her pelvis, lowers extremities and ribs. Whiting expects past and future medical and life care expenses in excess of $100,000. Whiting and her parents, Vickie and Willie Edwards, are seeking compensatory and punitive damages, pre- and post-judgment interest, and any other general and specific relief.
Case number: 09-C-284
James R. Christian Administrator of the Estate of Pansy Mae Christian v Mylan Pharmaceuticals, Inc., Actavis Group, Actavis Totowa, LLC, Mylan Bertek Pharmaceuticals, Inc. and UDL Laboratories, Inc.
P/A Tony L. O'Dell; Judge
* Suffering from a cardiac condition, Pansy May Christian was prescribed Digitek (Digoxin) by her physician. After taking the drug, Christian suffered physical impairment and died on November 8, 2007. James Christian received notice of the drug's recall in May 2008. It is believed that since 2006, the defendants have received at least eleven, maybe more, complaints about the significant adverse side effects of the drug. James Christian is seeking judgment from the defendants, jointly and severally, pre and post judgment interest, costs and attorney fees.
Case number: 09-C-292
Jeanette Lucineo, Administratix if the estate of Gary Lucineo v Mylan Pharmaceuticals, Inc., Actavis Group, Actavis Totowa, LLC, Mylan Bertek Pharmaceuticals, Inc. and UDL Laboratories, Inc.
P/A Teresa C. Toriseva; Judge NA
* Gary Lucineo suffered from congestive heart failure and was prescribed Digitek (Digoxin) by his physician. As a result of his taking the prescribed drug, he suffered toxicity and died on January 15, 2008. Jeanette Lucineo claims the defendants failed to warn users of the drug because the medication was provided for use by the public with twice the approved level of active ingredient. Digitek (Digoxin) has a narrow therapeutic index and as such, has a limited margin between effectiveness and toxicity, and any ingestion of excessive levels of the active ingredient beyond the level approved by the FDA can cause other health problems, and even death. As a result, Lucineo is seeking judgment, jointly and severally, pre- and post-judgment interest, costs and attorney fees.
Case number: 09-C-300